Company Filing History:
Years Active: 2018
Title: Innovations of Hongbin Yan in Diabetes Treatment
Introduction
Hongbin Yan is a prominent inventor based in Shanghai, China. He has made significant contributions to the field of biotechnology, particularly in the development of therapeutic proteins for the treatment of diabetes and obesity. His innovative work has the potential to improve the quality of life for many individuals suffering from these conditions.
Latest Patents
Hongbin Yan holds a patent for a long-acting blood sugar decreasing fusion protein. This invention provides an anthropogenic glucagon-like peptide-1 (GLP-1) recombinant protein molecule fused with an anthropogenic immunoglobulin subtype (IgG2) Fc section. The preparation method and purpose of this fusion protein are noteworthy. The fusion protein exhibits the biological activity of GLP-1 and has a significantly prolonged half-life in vivo. It can be utilized to treat type II diabetes, obesity, and other diseases by decreasing serum glucose, suppressing gastrointestinal motility, and reducing food intake.
Career Highlights
Hongbin Yan is associated with Genor Biopharma Co., Ltd., where he continues to advance his research and development efforts. His work in the biotechnology sector has garnered attention for its innovative approach to addressing metabolic disorders.
Collaborations
Some of his notable coworkers include Joe Zhou and Qing Zhou. Their collaboration has contributed to the success of various projects within the company.
Conclusion
Hongbin Yan's contributions to the field of diabetes treatment through his innovative patent highlight the importance of research in biotechnology. His work exemplifies the potential for scientific advancements to create effective therapies for chronic health conditions.